The China Mail - Drew Weissman, Nobel-winning mRNA pioneer

USD -
AED 3.673028
AFN 71.999738
ALL 87.274775
AMD 390.940193
ANG 1.80229
AOA 912.000387
ARS 1137.970101
AUD 1.565349
AWG 1.8
AZN 1.704736
BAM 1.720686
BBD 2.017877
BDT 121.428069
BGN 1.721593
BHD 0.376901
BIF 2930
BMD 1
BND 1.312071
BOB 6.906563
BRL 5.808198
BSD 0.999437
BTN 85.314611
BWP 13.77569
BYN 3.270808
BYR 19600
BZD 2.007496
CAD 1.384165
CDF 2877.000155
CHF 0.81849
CLF 0.025203
CLP 967.160244
CNY 7.300902
CNH 7.30369
COP 4310
CRC 502.269848
CUC 1
CUP 26.5
CVE 97.398863
CZK 22.038604
DJF 177.719867
DKK 6.56557
DOP 60.50261
DZD 132.565985
EGP 51.126903
ERN 15
ETB 133.023649
EUR 0.879325
FJD 2.283695
FKP 0.752659
GBP 0.753835
GEL 2.73998
GGP 0.752659
GHS 15.559986
GIP 0.752659
GMD 71.49558
GNF 8655.50116
GTQ 7.698128
GYD 209.656701
HKD 7.76252
HNL 25.908819
HRK 6.612098
HTG 130.419482
HUF 359.104997
IDR 16862.9
ILS 3.68395
IMP 0.752659
INR 85.3775
IQD 1310
IRR 42125.000166
ISK 127.589825
JEP 0.752659
JMD 157.965583
JOD 0.709303
JPY 142.17103
KES 129.498782
KGS 87.233498
KHR 4014.999894
KMF 433.489626
KPW 899.999997
KRW 1418.390422
KWD 0.30663
KYD 0.832893
KZT 523.173564
LAK 21630.000202
LBP 89600.000147
LKR 298.915224
LRD 199.974974
LSL 18.856894
LTL 2.95274
LVL 0.60489
LYD 5.470035
MAD 9.274983
MDL 17.289555
MGA 4552.892736
MKD 54.091003
MMK 2099.344606
MNT 3566.297198
MOP 7.990393
MRU 39.435529
MUR 45.089881
MVR 15.404613
MWK 1735.99973
MXN 19.72174
MYR 4.4075
MZN 63.905028
NAD 18.856894
NGN 1604.703383
NIO 36.775056
NOK 10.481075
NPR 136.503202
NZD 1.685133
OMR 0.384998
PAB 0.999437
PEN 3.763008
PGK 4.133235
PHP 56.712501
PKR 280.585566
PLN 3.762405
PYG 7999.894426
QAR 3.640595
RON 4.3781
RSD 103.137317
RUB 82.174309
RWF 1415
SAR 3.752237
SBD 8.368347
SCR 14.241693
SDG 600.500338
SEK 9.63369
SGD 1.310745
SHP 0.785843
SLE 22.774982
SLL 20969.483762
SOS 571.501393
SRD 37.149757
STD 20697.981008
SVC 8.745073
SYP 13001.855093
SZL 18.820132
THB 33.34705
TJS 10.733754
TMT 3.5
TND 2.987989
TOP 2.342097
TRY 38.12382
TTD 6.781391
TWD 32.524004
TZS 2687.499532
UAH 41.417687
UGX 3663.55798
UYU 41.913007
UZS 12986.521678
VES 80.85863
VND 25870
VUV 120.966432
WST 2.777003
XAF 577.111964
XAG 0.03066
XAU 0.000301
XCD 2.70255
XDR 0.717698
XOF 574.999952
XPF 102.774989
YER 245.2496
ZAR 18.839673
ZMK 9001.195457
ZMW 28.458439
ZWL 321.999592
  • RIO

    1.0100

    58.17

    +1.74%

  • NGG

    0.6300

    72.11

    +0.87%

  • RBGPF

    63.5900

    63.59

    +100%

  • CMSC

    0.0400

    21.82

    +0.18%

  • BTI

    0.5400

    42.37

    +1.27%

  • RELX

    1.0000

    52.2

    +1.92%

  • SCS

    0.0500

    9.76

    +0.51%

  • CMSD

    0.0400

    21.96

    +0.18%

  • RYCEF

    -0.1400

    9.36

    -1.5%

  • VOD

    0.1350

    9.305

    +1.45%

  • BCC

    0.7800

    93.47

    +0.83%

  • BP

    0.6600

    28.32

    +2.33%

  • GSK

    0.5600

    35.93

    +1.56%

  • JRI

    0.1600

    12.4

    +1.29%

  • BCE

    0.4200

    22.04

    +1.91%

  • AZN

    0.5400

    67.59

    +0.8%

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman, Nobel-winning mRNA pioneer / Photo: © AFP

Drew Weissman, Nobel-winning mRNA pioneer

Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.

Text size:

The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.

His next quests include, among others, developing a vaccine against all future coronaviruses.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."

- Twin breakthroughs-

The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.

But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.

In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.

- Helping people -

Weissman grew up in Lexington, Massachusetts.

His father and mother, both since retired, were an engineer and dental hygienist, respectively.

"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.

He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.

As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.

Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.

"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.

Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

N.Wan--ThChM